Disease free survival as surrogate end-point for overall survival in adjuvant taxane-based chemotherapy for breast cancer: Analysis of randomized clinical trials

被引：0
|
作者：
Ciccarese, M. [1 ]
Bria, E. [1 ]
Cuppone, F. [1 ]
Nistico, C. [1 ]
Carlini, P. [1 ]
Natoli, G. [1 ]
Nuzzo, C. [1 ]
Terzoli, E. [1 ]
Cognetti, F. [1 ]
Giannarelli, D. [1 ]
机构：
[1] Regina Elena Inst Canc Res, Dept Med Oncol, Rome, Italy
来源：
ANNALS OF ONCOLOGY | 2006年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：XI15 / XI15
页数：1
相关论文
共 50 条
  • [41] Progression-free survival and time to progression as surrogate markers of overall survival in patients with advanced gastric cancer: analysis of 36 randomized trials
    Shitara, Kohei
    Ikeda, Junko
    Yokota, Tomoya
    Takahari, Daisuke
    Ura, Takashi
    Muro, Kei
    Matsuo, Keitaro
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (03) : 1224 - 1231
  • [42] Objective response to chemotherapy as a potential surrogate end point of survival in metastatic breast cancer patients
    Bruzzi, P
    Del Mastro, L
    Sormani, MP
    Bastholt, L
    Danova, M
    Focan, C
    Fountzilas, G
    Paul, J
    Rosso, R
    Venturini, M
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (22) : 5117 - 5125
  • [43] Neoadjuvant chemotherapy response, disease-free survival, and overall survival of breast cancer in a single institution
    Prihantono
    Faruk, Muhammad
    SURGERY OPEN SCIENCE, 2023, 15 : 19 - 25
  • [44] Tumor-infiltrating lymphocytes to predict survival to anthracycline/taxane-based neoadjuvant chemotherapy in breast cancer.
    Ou, Qiyun
    Yu, Yunfang
    Xiao, Xiaoyun
    Luo, Baoming
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (05)
  • [45] Progression-free survival as an end-point in solid tumours - Perspectives from clinical trials and clinical practice
    Robinson, Andrew G.
    Booth, Christopher M.
    Eisenhauer, Elizabeth A.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 (13) : 2303 - 2308
  • [46] Disease-free survival as a surrogate for overall survival in HR+/HER2-early breast cancer: A correlation analysis
    Untch, Michael
    Perol, David
    Mayer, Erica L.
    Cortes, Javier
    Nusch, Arnd
    Cameron, David
    Barrios, Carlos
    Delea, Thomas
    Danyliv, Andrii
    Mishra, Namita
    Gupta, Rhea
    Pathak, Purnima
    Fasching, Peter A.
    EUROPEAN JOURNAL OF CANCER, 2024, 202
  • [47] Overall Survival and Post-Progression Survival in Advanced Breast Cancer: A Review of Recent Randomized Clinical Trials
    Saad, Everardo D.
    Katz, Artur
    Buyse, Marc
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (11) : 1958 - 1962
  • [48] A meta-analysis of randomized, controlled trials in metastatic melanoma establishes progression-free survival as a surrogate for overall survival
    Flaherty, K. T.
    Lee, S. J.
    Dummer, R.
    Hauschild, A.
    Hennig, M.
    Long, G. V.
    Lorigan, P.
    Robert, C.
    Schadendorf, D.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S856 - S856
  • [49] Progression-free survival as a surrogate endpoint for overall survival in modern ovarian cancer trials: a meta-analysis
    Sjoquist, Katrin M.
    Lord, Sarah J.
    Friedlander, Michael L.
    Simes, Robert John
    Marschner, Ian C.
    Lee, Chee Khoon
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2018, 10 : 1 - 16
  • [50] Progression-Free Survival as a Surrogate for Overall Survival in Advanced/Recurrent Gastric Cancer Trials: A Meta-Analysis
    Paoletti, Xavier
    Oba, Koji
    Bang, Yung-Jue
    Bleiberg, Harry
    Boku, Narikazu
    Bouche, Olivier
    Catalano, Paul
    Fuse, Nozomu
    Michiels, Stefan
    Moehler, Markus
    Morita, Satoshi
    Ohashi, Yasuo
    Ohtsu, Atsushi
    Roth, Arnaud
    Rougier, Philippe
    Sakamoto, Junichi
    Sargent, Daniel
    Sasako, Mitsuru
    Shitara, Kohei
    Thuss-Patience, Peter
    Van Cutsem, Eric
    Burzykowski, Tomasz
    Buyse, Marc
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2013, 105 (21): : 1667 - 1670
12345